Praxis Precision Medicines Inc Ordinary Shares PRAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
-
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
-
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
-
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
-
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
-
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Trading Information
- Previous Close Price
- $57.43
- Day Range
- $55.37–61.44
- 52-Week Range
- $13.01–67.21
- Bid/Ask
- $60.00 / $61.87
- Market Cap
- $1.09 Bil
- Volume/Avg
- 1 / 260,722
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 439.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 82
- Website
- https://www.praxismedicines.com
Comparables
Valuation
|
Metric
|
PRAX
|
ELYM
|
APLT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.59 | 1.54 | 13.31 |
Price/Sales | 439.39 | — | 2,956.31 |
Price/Cash Flow | — | — | — |
Price/Earnings
PRAX
ELYM
APLT
Financial Strength
|
Metric
|
PRAX
|
ELYM
|
APLT
|
|---|---|---|---|
Quick Ratio | 17.06 | 59.65 | 2.21 |
Current Ratio | 17.30 | 60.41 | 2.30 |
Interest Coverage | — | — | — |
Quick Ratio
PRAX
ELYM
APLT
Profitability
|
Metric
|
PRAX
|
ELYM
|
APLT
|
|---|---|---|---|
Return on Assets (Normalized) | −45.06% | −45.38% | −80.98% |
Return on Equity (Normalized) | −50.45% | −46.50% | −319.42% |
Return on Invested Capital (Normalized) | −49.77% | −46.38% | −315.20% |
Return on Assets
PRAX
ELYM
APLT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qjwvppyq | Kvw | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rcxfmmtc | Jznwjkg | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rgvymbplp | Dyqcl | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bcmvfhcm | Vtyymz | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Dpgskylm | Dhh | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Hhwqlvwnj | Kts | $28.3 Bil | |||
| Moderna Inc
MRNA
| Wtyqkbrrk | Fwvl | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Hrfcmlz | Wxsny | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bhqzbjff | Nddntbz | $13.3 Bil | |||
| Incyte Corp
INCY
| Ttzxcvlk | Vkcxrsy | $13.0 Bil |
United States